India’s largest drugmaker, Sun Pharmaceutical Industries, surged 9% on Monday’s early trades. This happened after it announced the acquisition of a definitive agreement to acquire US-listed Organon & Co. in an all-cash deal valued at $11.75 billion. It will acquire all outstanding shares of Organon for $14 per share.

The acquisition, the largest-ever overseas buyout by an Indian pharmaceutical firm, is designed to propel Sun Pharmaceutical Industries into the top 25 global pharma companies. 

Sun Pharmaceutical Industries reached an intraday high of ₹1,766.90 apiece, however, it remained ~5% below its 52-week high of ₹1,851.20. 

Strategic Pivot: Organon, a Merck (MSD) spin-off, brings a massive portfolio of over 70 products in women’s health, biosimilars, and established brands.

Global Footprint: The deal grants Sun Pharmaceutical Industries access to manufacturing facilities in the European Union and significant market share in China, Brazil, and the US.

Revenue Impact: Combined revenues are expected to hit $12.4 billion, with “Innovative Medicines” now projected to contribute nearly 27% of total revenue share, as per the exchange filing.

Sun Pharmaceutical Industries recently reported its results for the year ended 31st March 2026:

Particulars (₹ in Crores)Year Ended 31.03.2025 (Audited)Year Ended 31.03.2024 (Audited)% Change (YoY)
Total Revenue from Operations52,578.44 Cr48,496.90 Cr+8.42%
Net Profit for the Year10,929.04 Cr9,558.70 Cr+14.34%
Earnings Per Share (EPS) (₹)45.6 Cr39.8 Cr+14.57%